192results about "Transferrins" patented technology

This invention discloses a milk protein containing composition comprising: at least one milk protein; at least a first protein; at least a second protein; and at least a linker comprising an amino acid sequence coded by nucleotide sequence which is at least 80% similar to sequences selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21

The invention discloses a method for screening high-yield recombinant human lactoferrin through nucleic acid aptamer-assisted mutagenesis of a trichoderma reesei strain and application, and belongs to the technical field of microorganisms. The nucleic acid aptamer Lac-6a-FAM-BHQ1 capable of changing the fluorescence intensity according to the content of lactoferrin is constructed on the basis of the aptamer Lac-6a, and the nucleic acid aptamer can be used for rapidly selecting a mutant strain for producing high-titer recombinant human lactoferrin. The ARTP mutagenesis technology is combined with a nucleic acid aptamer auxiliary screening system, the mutant strain with the improved recombinant human lactoferrin yield is rapidly obtained from a large number of mutant strains, and the yield reaches 274.57 mg / L and is improved by 24.8% compared with that of an original strain. After the genes 111681 and 62716 are over-expressed in T. reesei, compared with a control strain, the yields of the recombinant human lactoferrin of the recombinant strain are respectively increased by 6.9% and 22.1%.

The efficacy and indication of donanemab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

The invention relates to human lactoferrin for use in enhancing bone strength and / or bone growth in a subject.

The application discloses a kind of diflufenican hapten, antigen, antibody and its preparation method and application.The application prepares diflufenican hapten as shown in formula (I) and corresponding diflufenican antigen, and specific antibody for detecting diflufenican is prepared by diflufenican antigen, and further constructs the immune analysis method for directly detecting diflufenican pesticide residue, which is particularly suitable for on-site rapid detection, and can meet the needs of regulatory authorities and detection agencies formula (I).

This invention provides a side-chain coupled compound of a cell-binding molecule having a branched linker and an amanita toxin compound. [Solution] A side-chain conjugated compound of formula (I), TIFF2026097851000286.tif25170 In one embodiment, a side-chain conjugated compound is provided, in which T is a cell-binding agent / molecule, W is a C1-C18 extension unit, and D is an amanita toxin, or an isotope of a chemical element, or a pharmaceutically acceptable salt, hydrate, or hydrated salt; or a polymorphic crystal; or an optical isomer, racemate, diastereomer, or enantiomer thereof.

The application relates to a detection method of oxicams for non-diagnostic purposes, and the application obtains a new oxicam hapten by optimizing the design of spatial configuration and chemical characteristics, and significantly improves the immunization efficiency of an antibody and the performance of an immunodetection device. The universal oxicam immunodetection device developed by the application integrates high sensitivity, wide detection range, anti-interference capability and rapid portability, overcomes the defects of the prior art, provides an efficient and reliable solution for rapid screening of oxicams in samples, and has significant technical progress and wide application prospect.

The invention relates to the technical field of biology, in particular to a recombinant pichia pastoris engineering bacterium, a construction method of the recombinant pichia pastoris engineering bacterium and application of the recombinant pichia pastoris engineering bacterium in secretory expression of ovotransferrin. The heterologous expression of ovotransferrin is effectively realized by optimizing ovotransferrin genes and utilizing molecular chaperone genes to strengthen the regulation and control capability of hosts, and meanwhile, by optimizing signal peptides and constructing high-copy recombinant pichia pastoris expression strains, the low-copy expression condition is verified and compared by utilizing fermentation expression, so that the heterologous expression of ovotransferrin is realized. According to the high-copy recombinant pichia pastoris engineering bacteria constructed by the invention, the ovotransferrin expression quantity is obviously improved and reaches 140 mg / L, the secretory expression efficiency of the ovotransferrin is effectively improved, and theoretical guidance is provided for heterologous expression and industrial production of the ovotransferrin.

In some aspects, the present invention provides chimeric transferrin receptor (TfR) polynucleotides and polypeptides. In other aspects, this invention provides chimeric TfR transgenic animal models and methods of using the animal models to identify therapeutics that can cross the blood-brain barrier.

The invention discloses a polypeptide module for promoting protein expression. The polypeptide module is polypeptide with an amino acid sequence as shown in SEQ ID NO: 2, wherein the polypeptide is formed by connecting a C end of a saccharomyces cerevisiae source signal peptide alpha-factor Pro section with two acidic residues EA; the composite signal peptide is formed by connecting a signal peptide OST1 from saccharomyces cerevisiae to the polypeptide module at the C end, the fusion expression of the composite signal peptide and the exogenous recombinant protein in saccharomycetes can improve the expression and secretion of the exogenous recombinant protein, and the composite signal peptide has popularization and application prospects.

The efficacy and indication of natalizumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

The application discloses a novel lactoferrin inducible soluble expression system and a construction method thereof, and belongs to the technical field of biotechnology and genetic engineering, and the specific scheme is that human lactoferrin (LF) is expressed by probiotic Escherichia coli Nissle1917, the protein is purified after the expression position is determined, and anti-inflammatory activity is determined. The LF expression system constructed by the application provides a construction method of a prokaryotic expression stable human lactoferrin expression vector, the vector is introduced into probiotic Escherichia coli Nissle1917, soluble target recombinant human lactoferrin is obtained after induction fermentation expression, two-step purification and identification, and the application has the characteristics of high safety, low cost, easy operation and the like.

The application provides an optimized lactoferricin peptide, a preparation method thereof and application thereof in preparation of anti-inflammatory and anti-oxidative damage preparations, and belongs to the technical field of biological medicines.The application obtains high-biological-activity lactoferricin peptide by optimizing amino acid sites of lactoferricin B; compared with the original lactoferricin B, the optimized lactoferricin peptide has better anti-inflammatory and anti-oxidative effects, can effectively reduce alcohol-induced oxidative damage, fatty degeneration and apoptosis of liver cells, and promote recovery of liver function.The lactoferricin peptide provided by the application can reduce the elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels by about 25% and 20%, respectively.The application provides an application scheme in development of a new generation of polypeptide drugs for treating alcoholic liver disease, hepatitis, acute lung injury and various inflammation oxidative stress related diseases.

The invention belongs to the technical field of genetic engineering, and particularly relates to application of diaphorina citri transferrin Tsf in prevention and control of citrus huanglongbing. The invention provides an application of diaphorina citri transferrin Tsf in prevention and control of citrus huanglongbing. A nucleotide sequence for coding a gene of the diaphorina citri transferrin Tsf is shown as SEQ ID NO.1. The invention further provides a preparation method of the diaphorina citri transferrin Tsf. According to the invention, the expression of transferrin Tsf in diaphorina citri can be interfered, so that the infection ability of Candidatus Liberobacter asiaticum can be reduced, the bacterium carrying amount can be reduced, a new strategy is provided for effective prevention and control of the Candidatus Liberobacter asiaticum, and a new prevention and control idea is provided for controlling propagation of bacterial pathogens by means of vector insects.

The efficacy and indication of adalimumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors

A protein polymer and a production process therefor. The protein polymer is obtained by means of stimulating MSCs, lysing same, and separating and purifying same. The protein polymer has a strong capability to repair oxidative damage, and thus can reduce the range of cerebral infarction, improve neural functions, inhibit the level of neuroinflammation, and increase the number of surviving neurons.

The present application relates to oligonucleotides (e.g., antisense oligonucleotides such as gapmers) designed to target DMPK RNAs and targeting complexes for delivering the oligonucleotides to cells (e.g., muscle cells) and uses thereof, particularly uses relating to treatment of disease. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DMPK.

Disclosed herein are methods for the production of novel topically-adherent selective bactericides and products resulting therefrom, more specifically, methods for the production of complexed stable microbiome-regulating proteins configured for topical administration, and the use of such products as pharmaceuticals effective in treating pathogenic bacteria, but not commensal bacteria.

The efficacy and indication of ranibizumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

Methods for altering leptin resistance and the hormonal control of energy balance, and methods for treating obesity and diabetes, as well as promoting weight gain, using batotin and batotin inhibitors.

This invention relates to a nutritional composition comprising a combination of β-lactoglobulin and lactoferrin. β-Lactoglobulin is a major whey protein with excellent emulsifying and gelling properties, while lactoferrin is known for its antimicrobial and immune-modulating effects. The combination of these proteins provides enhanced health benefits such as improved immune support and gut health. A key feature of this invention is the ability of β-lactoglobulin to prevent or reduce the coagulation of lactoferrin during heating, maintaining its functional integrity and efficacy. Additionally, methods for recombinantly producing lactoferrin and β-lactoglobulin, and specific formulations for targeted demographics such as children, infants, and the elderly, and formulations for healthy ageing, for improvement of women's health and / or as a sports nutrition composition are disclosed.

The efficacy and indication of ALEMTUZUMAB do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

Described are dual transporters and methods of making and using the dual transporters. The dual transporters bind to a blood brain barrier transport protein and a second protein that is expressed on the luminal surface of the blood brain barrier or is a brain retention protein. The dual transporters improve delivery to the central nervous system.

Provided is an application of a protein polymer in the preparation of a drug for treating autism. Research has found that protein polymers derived from mesenchymal stem cells stimulated under stress conditions, such as ultraviolet irradiation, have a certain therapeutic effect on autism, providing a possibility for the treatment of autism.

The efficacy and indication of MEDI1341 do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

The efficacy and indication of dupilumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

The invention discloses a chloramphenicol hapten, antigen, antibody and colloidal gold detection device as well as a preparation method and application thereof. According to the chloramphenicol hapten prepared by using a total synthesis method, all potential recognition sites of chloramphenicol are reserved to the maximum extent, particularly, the most critical dichloro structure of chloramphenicol is reserved for the first time, after a spacer arm is introduced, the distribution of electron cloud of the hapten is almost consistent with that of overall electron cloud of chloramphenicol, and the immunogenicity of the chloramphenicol antigen is improved; the chloramphenicol antigen and the monoclonal antibody prepared by the invention are high in specificity when being used for ELISA detection, the IC50 value is 8.21 pg / mL, the linear detection range is 1.71-39.45 pg / mL, and the cross reaction rates of the chloramphenicol antigen and the monoclonal antibody to common structural analogues are lower than 0.01%; and the sensitivity to chloramphenicol in a sample is 0.1 g / kg.

The invention relates to a chlorantraniliprole hapten, a complete antigen and application of the chlorantraniliprole hapten and the complete antigen. When the chlorantraniliprole artificial antigen and the monoclonal antibody are used for ELISA detection, the specificity is high, the IC50 value is 0.058 [mu] g / L, the detection limit of chlorantraniliprole in a standard solution reaches 0.6 [mu] g / L, and the detection limit of a sample to be detected reaches 2 g / kg; the cross reaction rates with cyantraniliprole, tetrachlorantraniliprole and cyclaniliprole are respectively 20%, 12% and 12%, and the material specificity is greatly improved. By utilizing the chlorantraniliprole hapten, the complete antigen and the antibody, the purpose of rapidly and accurately detecting chlorantraniliprole in a sample can be achieved.

The efficacy and indication of solanezumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

The present invention relates to a method for producing lactoferrin, comprising the steps: a) providing (102) a starting material, which is selected from a group comprising skimmed milk, casein-free milk, e.g., cheese whey, and skimmed colostrum, b) chromatographically extracting (117) liquid lactoferrin from the starting material, c) desalinating (120) the liquid lactoferrin by means of ultrafiltration, and d) sterile filtering (126) the desalinated liquid lactoferrin, wherein the sterile filtered liquid lactoferrin with a dry mass content of ≤25% has a shelf life in uncooled storage of at least three months, preferably at least six months, and particularly preferably at least 24 months. An apparatus (300) for producing lactoferrin comprises: - a chromatography column (317) which is designed for chromatographically extracting liquid lactoferrin from a starting material, which is selected from a group comprising skimmed milk, casein-free milk, e.g., cheese whey, and skimmed colostrum, - an ultrafiltration device (320) which is designed for desalinating the liquid lactoferrin by means of ultrafiltration, - a sterile filtration device (326) which is designed for sterile filtering of the desalinated liquid lactoferrin in order to obtain a shelf life of the sterile filtered liquid lactoferrin with a dry mass content of ≤25% in uncooled storage of at least three months, preferably at least six months, and particularly preferably at least 24 months, and - a control device (333) designed and configured for controlling the chromatography column (317), the ultrafiltration device (320) and the sterile filtration device (326) in order to produce the sterile filtered, liquid and storable lactoferrin from the starting material. The present invention also relates to lactoferrin produced by the above-described method and to different uses of the lactoferrin produced by the above-described method as an ingredient or additive.